For many biotech innovators, high-throughput screening platforms promise faster discoveries and streamlined workflows. Yet beneath the surface, the reality is more demanding, requiring hands-on expertise, careful assay design, and a sharp understanding of microbial physiology to avoid mistakes that become expensive to fix downstream.

David Brühlmann continues his conversation with Sebastian Blum, Market Development Manager in Europe at Beckman Coulter Life Sciences, who brings a practical, unvarnished perspective to high-throughput screening. Drawing on conversations with startups, pharma, and CDMOs, Sebastian digs into what separates "push-button" automation myths from hard-won bioprocess mastery. From evaluating technical fit to troubleshooting real-world applications, he advocates for a nuanced approach, one focused on fit-for-purpose tools and critical thinking over technology hype.

In this episode, we discuss:

• Practical advice for startups considering systems like the BioLector XT Microbioreactor, including the need for technical expertise and tailored applications (02:34)
• Scenarios where the BioLector XT Microbioreactor is the best fit (flexibility, multiple microorganisms, modular upgrades) (04:22)
• The most common mistakes scientists make with screening technologies, and why specialized personnel are still essential (06:45)
• How automation, robotics, and AI are shaping the future of early-stage bioprocess development, and why core engineering principles remain vital (08:14)
• Tips for evaluating screening tool placement in your process and aligning technology with your application needs (11:13)

If you're making decisions about high-throughput screening platforms and want to avoid costly missteps before scale-up, this episode delivers the clarity you need.

Connect with Sebastian Blum:

LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3b

Beckman Coulter Life Sciences: www.beckman.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

Why do so many promising biotech ideas stall long before they reach the clinic or marketplace? For many, the answer lies hidden in the earliest phase of bioprocess development: upstream processing. It’s where strain selection, media optimization, and culture conditions set the stage for everything that follows. Yet, the smallest missteps here can snowball into expensive roadblocks downstream. This episode of Smart Biotech Scientist Podcast zeros in on why smart screening strategies and the right bioreactor choices early on are the difference between breakthrough and bottleneck.

Joining host David Brühlmann is Sebastian Blum, a microbiologist with more than two decades in the life sciences. As Market Development Manager at Beckman Coulter Life Sciences, Sebastian Blum brings firsthand knowledge from collaborating with startups, pharma giants, and CDMOs, bridging theory with the practical realities of modern process development. From commercializing micro-fermentation systems to guiding clients through high-throughput data, his insights come not just from research but real-world applications.

Key Topics & Insights:

• How startups versus large pharma companies differ in process development strategies, including the role of budget, resources, and risk management. (04:27)
• The importance of designing screening experiments that mirror end-process conditions, and misconceptions around batch versus fed-batch modes. (07:49)
• Overview of available small-scale bioreactor systems: shake flasks, benchtop reactors, and high-throughput platforms—pros, cons, and ideal use cases. (09:17)
• Detailed comparison of BioLector XT Microbioreactor, ambr® 15, and ambr® 250 systems, including working volumes, experiment throughput, measurement technology, and cell types suited for each. (13:24)
• Practical guidance on making the most of high-throughput screening tools and how training, scripting, and collaboration help new users get value from systems like the BioLector XT Microbioreactor. (17:00)

This episode offers grounded advice for scientists and founders navigating early-stage bioprocess development, plus a clear look at the technology landscape for microbial screening and optimization. Perfect for those looking to streamline process development and avoid common pitfalls.

Connect with Sebastian Blum:

LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3b

Beckman Coulter Life Sciences: www.beckman.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months.

Meet Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, a scientist who didn't settle for the status quo. As the driving force behind the company, she led the charge to cut through process bottlenecks: navigating regulatory hurdles, scaling plant-based vaccine manufacturing to 5 million doses per month, and reshaping the approach to antibody production for oncology and infectious diseases. Her work proved that plants aren't an alternative. They're a platform.

Topics discussed include:

• How plant-based molecular farming compares to traditional microbial and mammalian cell systems (02:44)
• The flexibility and rapid scalability of using plants for biomanufacturing (05:06)
• Speeding up process development with transient expression versus transgenic plants (05:45)
• Regulatory perspectives and the approval process for plant-produced biologics (06:52)
• An overview of the ongoing oncology and infectious disease antibody pipeline (08:08)
• Strategic challenges: balancing product development, revenue, and market-ready innovations through subsidiary companies (09:51)
• Lessons learned from building a GMP facility capable of 5 million doses per month during the pandemic, with supply chain as the biggest bottleneck (12:50)
• Future innovations in molecular farming and the role of plant platforms in medicine production (14:47)

Smart insight:

Platform choice matters. If you're struggling with long development timelines or scale-up challenges, it may not always be the molecule. It may be the system you're using. Molecular farming offers a different set of trade-offs: faster development, flexible scaling, and a practical alternative worth considering before defaulting to a single platform.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:

• Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
• Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
• Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Connect with Waranyoo Phoolcharoen:

Email: Waranyoo.P@baiyaphytopharm.com

Baiya Phytopharm website: www.baiyaphytopharm.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

Imagine producing life-saving antibodies or vaccines not in sprawling stainless steel facilities, but in sunlit greenhouses, inside living, breathing plants.

Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, leads the charge in molecular farming in Thailand, pioneering a shift from traditional biomanufacturing toward using whole plants as responsive biofactories. With a unique background in both pharmaceutical sciences and plant biotechnology, she has taken her research out of the academic silo and into the world, founding a clinical-stage company determined to make vaccines and therapeutic proteins accessible where they're needed most.

In this episode, we cover:

• Waranyoo Phoolcharoen's personal journey: from an accidental start in plant biotechnology to making a global impact with molecular farming (03:57)
• The pivotal moment that shifted her focus from publishing papers to translating research into real-world solutions (06:12)
• The initial steps and uncertainties of co-founding Baiya Phytopharm in Thailand (07:12)
• How 'the plant of life' philosophy drives their biopharma platform, and why whole plants (not just cell cultures) are used as biofactories (09:56)
• Key mindset shifts when transitioning from academia to entrepreneurship, including the importance of teamwork and commercial thinking (12:55)
• Strategies for making impact-driven biotech startups in resource-constrained environments, and why courage and speed matter (15:50)
• Insights into the biotech and pharmaceutical landscape in Southeast Asia, including opportunities and challenges for innovators (19:27)

Smart insight:

The most important mindset shift from scientist to entrepreneur isn't technical; it's learning to ask different questions. Not "is this interesting?" but "who will pay for this, and does it make commercial sense?" As Waranyoo puts it, when you have the right question, it leads to the right answer.

Stay tuned for Part 2, where we'll explore platform capabilities and Asia's first plant-derived COVID-19 vaccine to enter clinical trials.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:

• Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
• Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
• Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Connect with Waranyoo Phoolcharoen:

Email: Waranyoo.P@baiyaphytopharm.com

Baiya Phytopharm website: www.baiyaphytopharm.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.

Support the show

Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions.

Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the realities of automation strategy in biotech. Drawing from years of building robotics for high-stakes labs, Anthony explores why "minimum testable product" consistently outperforms "minimum viable product" when budgets, timelines, and patient outcomes are on the line.

Highlights from the episode:

• When custom robotics development is genuinely justified — and the conditions that determine whether a large-scale automation investment makes sense for your organization (02:59).
• Tech demos and usability demos: how to test the hardest parts of your system concept in isolation before committing to full development (06:37).
• Minimum testable product vs. minimum viable product: why rushing to viable in hardware development is a costly mistake, and how controlled pilot deployments generate the learning that actually accelerates your program (07:37).
• Why testing in the real operating environment — not a simulated lab setting — is the only way to surface the hidden requirements that will determine whether your automation succeeds or fails (08:29).
• The "go fever" trap: why problems discovered late in development get buried rather than fixed, and how front-loading validation protects both your timeline and your budget (10:16).
• The single most practical question a biotech scientist can ask to determine whether a process is a genuine automation candidate: how much are you thinking while you do it? (16:02).
• Where AI and machine learning deliver real value in bioprocess research — and why the more urgent question is not how to automate a process, but how to redesign it to produce better data (17:59).
• Why capital equipment in biotech labs will need to change fundamentally to collect the volume and quality of data required to make AI-driven insights meaningful (19:01).

Smart insight: Automation is not a technology problem, it is a systems development and requirements development problem. The teams that deeply understand their process and environment before touching a line of code or a line of engineering will always outperform those that do not. As Anthony puts it: you need to look at the whole picture.

Connect with Anthony Catacchio:

LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b

Product Insight website: www.productinsight.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot.

In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation.

Highlights from the episode:

• Why biotech's "special case" mindset around automation is costing companies time and money — and what industrial robotics already has figured out (02:45).
• How Anthony's cross-industry career — from surgical devices to warehouse robotics — shaped a process-first approach to system design (05:05).
• The automation paradox: how to increase throughput and reduce errors without eliminating the expert human judgment your process depends on (09:13).
• Vision-guided robotics, AGVs, and quadrupeds: what has genuinely changed in capability and what that means for bioprocess applications (11:21).
• Human-bot testing: the low-cost validation method that reveals workflow flaws before a single robot is purchased (15:07).
• The $1M vs. $10K decision: a real case study where the right answer was walking away from automation entirely (15:54).
• Why talking a client out of an expensive project is sometimes the highest-value service a technical consultant can deliver (17:38).
• Building long-term credibility by recommending the simplest solution that actually solves the problem (19:24).

Smart insight: The most expensive automation mistake happens at the whiteboard, not on the manufacturing floor. Define the problem with surgical precision before you ever evaluate a solution.

In Part 2, the conversation continues with a deeper look at building automation systems that deliver practical solutions to bioprocessing challenges without overengineering.

Tune in for practical strategies and honest reflections on automation, system design, and the importance of clear problem definition in biotech hardware development.

Connect with Anthony Catacchio:

LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b

Product Insight website: www.productinsight.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

How solid is your CMC foundation—and what happens if it cracks under pressure?

David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.

His “house building” approach demystifies CMC’s complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.

Tune in to hear Henri’s practical wisdom distilled through real-world analogies:

• Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)
• Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)
• Process validation explained: FDA’s three stages, from control strategy justification to continued verification (05:15)
• Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)
• Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)
• Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)
• Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)
• The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)

Smart insight:

Never underestimate CMC. If you do, you will pay for it later.

If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:

• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Connect with Henri Kornmann:

LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later.

Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His conclusion: a CMC program is like building a house. Get the foundation wrong and no amount of late-stage effort will save you.

In Part 1, Henri reveals the decisions that cannot be undone and how to get them right from the start.

What you will learn:

• Evolution of cell bank technology and regulatory expectations (00:33)
• The impact of weak CMC foundations on late-stage failure (00:51)
• Lessons learned from Ferring’s gene therapy approval and CMC gap analysis (06:51)
• FDA statistics on CMC issues in INDs and response letters (08:07)
• Critical early decisions: cell bank clonality and proper storage practices (10:22)
• The importance of comprehensive raw material documentation (12:29)
• Early analytical characterization and discovering molecular “funkiness” before phase trials (13:41)
• Supply strategy for phase 2—why stability and batch knowledge matter (14:49)
• Introduction to critical quality attributes (CQA), process parameters, and quality-by-design principles (15:52)
• Common pitfalls in CQA identification and continued process verification (17:01)

Smart insight:

The therapies that reach patients aren't built on heroic late-stage rescues. They're built on disciplined early decisions: the right cell bank, the right analytics, the right documentation. Henri's message is unambiguous: there are CMC mistakes you can fix later, and there are CMC mistakes you cannot. Knowing the difference is the foundation of every successful biologics program.

In Part 2, Henri walks through scale-up to commercial manufacturing, process validation stages 1 through 3, post-approval control strategy, and the project management and regulatory fluency that separate successful CMC leaders from the rest.

If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:

• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Connect with Henri Kornmann:

LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show